Mirum Pharmaceuticals (MIRM) Cost of Revenue (2021 - 2026)

Mirum Pharmaceuticals' Cost of Revenue history runs 6 years deep, the most recent figure standing at $28.8 million for Q1 2026.

• In Q1 2026, Cost of Revenue rose 25.14% year-over-year to $28.8 million; the TTM figure through Mar 2026 stood at $106.0 million (up 22.11% YoY), while the FY2025 annual figure was $100.2 million, up 22.78% from the prior year.
• Cost of Revenue for Q1 2026 stood at $28.8 million, up from $28.3 million in the prior quarter.
• The five-year high for Cost of Revenue was $28.8 million in Q1 2026, with the low at $2.4 million in Q1 2022.
• The 5-year median for Cost of Revenue is $20.2 million (2024), against an average of $15.9 million.
• The sharpest annual moves came in 2023 and 2024: Cost of Revenue soared 456.74% in 2023, then declined 8.95% in 2024.
• Mirum Pharmaceuticals' Cost of Revenue stood at $4.5 million in 2022, then jumped by 456.74% to $25.0 million in 2023, then declined by 8.95% to $22.8 million in 2024, then rose by 24.07% to $28.3 million in 2025, then increased by 1.91% to $28.8 million in 2026.
• Business Quant data shows MIRM's Cost of Revenue at $28.8 million in Q1 2026, $28.3 million in Q4 2025, and $25.5 million in Q3 2025.